{{Rsnum
|rsid=3759216
|Chromosome=12
|position=12715152
|Orientation=plus
|GMAF=0.3944
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene=LOC101929220
|Gene_s=LOC101929220
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 23.2 | 51.8 | 25.0
| HCB | 21.6 | 52.2 | 26.1
| JPT | 19.5 | 45.1 | 35.4
| YRI | 5.4 | 31.3 | 63.3
| ASW | 8.8 | 43.9 | 47.4
| CHB | 21.6 | 52.2 | 26.1
| CHD | 23.9 | 54.1 | 22.0
| GIH | 17.8 | 55.4 | 26.7
| LWK | 2.8 | 31.2 | 66.1
| MEX | 12.3 | 43.9 | 43.9
| MKK | 3.9 | 31.0 | 65.2
| TSI | 18.6 | 46.1 | 35.3
| HapMapRevision=28
}}{{PMID Auto
|PMID=21454826
|Title=Association of genetic polymorphisms in cell-cycle control genes and susceptibility to endometrial cancer among Chinese women
|OA=1
}}

{{PMID Auto
|PMID=18174243
|Title=Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.
|OA=1
}}

{{PMID Auto
|PMID=18543099
|Title=No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
}}

{{PMID Auto
|PMID=19258477
|Title=Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}